Article -> Article Details
| Title | Portugal Personalized Medicine Market Report Market Dynamics, and Growth Outlook, 2026–2034 |
|---|---|
| Category | Business --> Business Services |
| Meta Keywords | Portugal personalized medicine market |
| Owner | Neeraj kumar |
| Description | |
| Market Overview The Portugal personalized medicine market was valued at USD 2.49 Billion in 2025 and is projected to reach USD 5.48 Billion by 2034, exhibiting a CAGR of 9.18% during the forecast period 2026-2034. The market growth is driven by advancements in genomics, artificial intelligence (AI), and precision diagnostics, which enhance patient care and targeted therapies. Increased investments in infrastructure, skilled workforce, and clinical innovations are expanding applications in oncology, rare diseases, and chronic conditions. These factors are collectively shaping a patient-centric healthcare landscape in Portugal. Study Assumption Years
Portugal Personalized Medicine Market Key Takeaways
Sample Request Link: https://www.imarcgroup.com/portugal-personalized-medicine-market/requestsample Market Growth Factors The personalized medicine market in Portugal is mainly driven by genomic and molecular testing. Advances in sequencing and bioinformatics technologies enable physicians to prescribe targeted therapies to specific patients based on their genetic predisposition to diseases or their disease response profiles. It serves as the basis for selecting drugs/treatment dosages and minimizing adverse drug reactions, as well as the early diagnosis and prevention of disease. Personalizing treatment often leads to better outcomes, improved patient satisfaction, and more efficient use of healthcare resources. Applications of genomics-based therapeutics are expanding across many clinical specialties and are increasingly supported by research and infrastructure. AI and data analytics are used to improve access to precision genomics, and to deliver bespoke medicine. Partnering with, for example, Velsera and Diagnostica Longwood, predictive models of disease progression, treatment strategies and treatment response are derived through analysis of electronic health records and genomic datasets. This yields focused actions, identifying at-risk individuals through pattern recognition, and adapting treatment pathways to prevent unnecessary interventions and optimize resource use. This will lead to increased clinical use of AI in Portugal, operational and clinical efficiencies, and a clearer view of future trends in personalized medicine. Targeted therapies and combination therapies, including precision drugs targeting specific molecular aberrations and drug combinations to improve efficacy and prevent drug resistance, are changing clinical practice and informing the use of biomarkers to help establish the optimal drug combination therapy that will deliver the best possible outcomes in oncology, rare diseases, and chronic disease. Individualized regimes improve quality of life and medication adherence of patients. New innovations are expected to affect the adoption and precision of healthcare delivery and the personalized medicine market forecast in Portugal. Market Segmentation Analysis by Product:
Analysis by End Use:
Request Customization: https://www.imarcgroup.com/request?type=report&id=44250&flag=E Regional Insights The Portugal personalized medicine market encompasses key regions including Norte, Centro, A. M. Lisboa, Alentejo, and other areas. While specific statistics by region are not detailed in the source, these regions collectively contribute to the overall market growth by hosting healthcare institutions, research centers, and technology platforms that drive personalized medicine adoption across the country. This regional spread supports comprehensive market coverage and reflects the national scale of personalized healthcare initiatives. Recent Developments & News In June 2025, NOVA FCT joined the CAR T-Matters project, collaborating with Portuguese research and clinical institutions to develop CAR T cell therapies for cancer. The project aims to establish a national production capacity, reduce reliance on international facilities, and accelerate clinical translation to expand patient access to innovative personalized immunotherapies in Portugal. In December 2024, the European Partnership in Personalized Medicine (EP PerMed) launched its second Joint Transnational Call, PGxPM2025, focusing on pharmacogenomic strategies for personalized medicine. Portuguese entities FCT, AICIB, CCRDC, and DRCID are participating to support cross-border research initiatives that identify and validate pharmacogenomic markers and optimize individualized therapies. Key Players
Customization Note If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization. About Us IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research. Contact Us IMARC Group 134 N 4th St. Brooklyn, NY 11249, USA Email: sales@imarcgroup.com Tel No: (D) +91 120 433 0800 United States: +1-201971-6302 | |